News coverage about Apollo Endosurgery (NASDAQ:APEN) has trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.08 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.7689399707746 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Apollo Endosurgery Inc (APEN) Expected to Post Quarterly Sales of $16.00 Million (americanbankingnews.com)
- Apollo Endosurgery (APEN) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Stonepine Capital Management LLC Has $14.34 Million Holdings in Apollo Endosurgery Inc (APEN) (americanbankingnews.com)
- Analysts Expect Apollo Endosurgery Inc (APEN) Will Announce Earnings of -$0.34 Per Share (americanbankingnews.com)
Apollo Endosurgery (NASDAQ:APEN) opened at $6.20 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.00 and a current ratio of 2.23. Apollo Endosurgery has a 12 month low of $3.55 and a 12 month high of $14.09. The firm has a market cap of $108.94, a P/E ratio of -2.88 and a beta of 0.46.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. acquired 45,434 shares of the company’s stock in a transaction dated Wednesday, December 20th. The stock was acquired at an average cost of $4.50 per share, with a total value of $204,453.00. Following the purchase, the insider now directly owns 2,410,141 shares in the company, valued at approximately $10,845,634.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have bought 263,886 shares of company stock valued at $1,288,051. Corporate insiders own 74.20% of the company’s stock.
WARNING: “Apollo Endosurgery (APEN) Earning Somewhat Favorable News Coverage, Report Finds” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3253902/apollo-endosurgery-apen-earning-somewhat-favorable-news-coverage-report-finds.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.